RU2019102647A - Антипролиферационные средства на основе пиримидина - Google Patents
Антипролиферационные средства на основе пиримидина Download PDFInfo
- Publication number
- RU2019102647A RU2019102647A RU2019102647A RU2019102647A RU2019102647A RU 2019102647 A RU2019102647 A RU 2019102647A RU 2019102647 A RU2019102647 A RU 2019102647A RU 2019102647 A RU2019102647 A RU 2019102647A RU 2019102647 A RU2019102647 A RU 2019102647A
- Authority
- RU
- Russia
- Prior art keywords
- alkylene
- alkyl
- compound according
- cycloalkyl
- compound
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/20—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/14—Ortho-condensed systems
- C07D491/147—Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D495/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662357630P | 2016-07-01 | 2016-07-01 | |
| US62/357,630 | 2016-07-01 | ||
| PCT/US2017/040093 WO2018005860A1 (en) | 2016-07-01 | 2017-06-29 | Pyrimidine-based antiproliferative agents |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2019102647A true RU2019102647A (ru) | 2020-08-03 |
| RU2019102647A3 RU2019102647A3 (cg-RX-API-DMAC7.html) | 2020-08-03 |
Family
ID=60787753
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2019102647A RU2019102647A (ru) | 2016-07-01 | 2017-06-29 | Антипролиферационные средства на основе пиримидина |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US10829490B2 (cg-RX-API-DMAC7.html) |
| EP (2) | EP3478294A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2019520379A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20190025943A (cg-RX-API-DMAC7.html) |
| CN (1) | CN109789143A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2017290748A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112018077136A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3028751A1 (cg-RX-API-DMAC7.html) |
| EA (1) | EA201990187A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL263910A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2019000200A (cg-RX-API-DMAC7.html) |
| RU (1) | RU2019102647A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2018005860A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109789143A (zh) * | 2016-07-01 | 2019-05-21 | G1治疗公司 | 基于嘧啶的抗增殖剂 |
| WO2018005863A1 (en) * | 2016-07-01 | 2018-01-04 | G1 Therapeutics, Inc. | Pyrimidine-based compounds for the treatment of cancer |
| JOP20170169A1 (ar) | 2016-08-29 | 2019-01-30 | Novartis Ag | مركبات بيريدازين ثلاثية الحلقة مندمجة تفيد في علاج العدوى بفيروس أورثوميكسو |
| IL317919A (en) | 2016-12-05 | 2025-02-01 | G1 Therapeutics Inc | Preservation of immune response during chemotherapy regimens |
| JP7229162B2 (ja) | 2017-01-06 | 2023-02-27 | ジー1 セラピューティクス, インコーポレイテッド | 癌の治療に対する併用療法 |
| CA3070073A1 (en) | 2017-07-18 | 2019-01-24 | Nuvation Bio Inc. | 1,8-naphthyridinone compounds and uses thereof |
| JP2020527588A (ja) | 2017-07-18 | 2020-09-10 | ニューベイション・バイオ・インコーポレイテッドNuvation Bio Inc. | アデノシンアンタゴニストとしてのヘテロ環式化合物 |
| WO2019161224A1 (en) | 2018-02-15 | 2019-08-22 | GiraFpharma LLC | Heterocyclic compounds as kinase inhibitors |
| HUE069183T2 (hu) | 2018-02-28 | 2025-02-28 | Novartis Ag | 10-(di(fenil)metil)-4-hidroxi-8,9,9a,10-tetrahidro-7H--pirrolo[1',2':4,5]pirazino[1,2-b]piridazin-3,5-dion származékok és kapcsolódó vegyületek mint orthomyxovírus repikáció gátlók influenza kezelésére |
| WO2019222521A1 (en) * | 2018-05-16 | 2019-11-21 | G1 Therapeutics, Inc. | Cdk inhibitors for the treatment of neoplastic disorders |
| CN109836400B (zh) * | 2018-09-17 | 2022-12-09 | 南通华祥医药科技有限公司 | 杂环化合物及其盐的制备方法 |
| US11066404B2 (en) | 2018-10-11 | 2021-07-20 | Incyte Corporation | Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors |
| EP3902805A4 (en) | 2018-12-28 | 2023-03-01 | SPV Therapeutics Inc. | CYCLINE-DEPENDENT KINASE INHIBITORS |
| CN111377921A (zh) * | 2018-12-29 | 2020-07-07 | 武汉光谷通用名药物研究院有限公司 | Cdk4-flt3抑制剂及其用途 |
| US11254670B2 (en) | 2019-01-18 | 2022-02-22 | Nuvation Bio Inc. | 1,8-naphthyridinone compounds and uses thereof |
| WO2020150674A1 (en) | 2019-01-18 | 2020-07-23 | Nuvation Bio Inc. | Heterocyclic compounds as adenosine antagonists |
| WO2020168197A1 (en) | 2019-02-15 | 2020-08-20 | Incyte Corporation | Pyrrolo[2,3-d]pyrimidinone compounds as cdk2 inhibitors |
| TW202100520A (zh) | 2019-03-05 | 2021-01-01 | 美商英塞特公司 | 作為cdk2 抑制劑之吡唑基嘧啶基胺化合物 |
| US11919904B2 (en) | 2019-03-29 | 2024-03-05 | Incyte Corporation | Sulfonylamide compounds as CDK2 inhibitors |
| WO2020206034A1 (en) * | 2019-04-01 | 2020-10-08 | G1 Therapeutics, Inc. | Cell cycle inhibiting compounds for the treatment of medical disorders |
| WO2020223558A1 (en) * | 2019-05-01 | 2020-11-05 | Incyte Corporation | Tricyclic amine compounds as cdk2 inhibitors |
| WO2020223469A1 (en) | 2019-05-01 | 2020-11-05 | Incyte Corporation | N-(1-(methylsulfonyl)piperidin-4-yl)-4,5-di hydro-1h-imidazo[4,5-h]quinazolin-8-amine derivatives and related compounds as cyclin-dependent kinase 2 (cdk2) inhibitors for treating cancer |
| US12522615B2 (en) | 2019-06-24 | 2026-01-13 | Boehringer Ingelheim International Gmbh | Macrocyclic compounds and derivatives as EGFR inhibitors |
| WO2021030537A1 (en) | 2019-08-14 | 2021-02-18 | Incyte Corporation | Imidazolyl pyrimidinylamine compounds as cdk2 inhibitors |
| US12570660B2 (en) | 2019-08-16 | 2026-03-10 | Cyclacel Pharmaceuticals, Inc | Process for the preparation of a pyrimidino-diazepine derivative |
| CR20220170A (es) | 2019-10-11 | 2022-10-10 | Incyte Corp | Aminas bicíclicas como inhibidoras de la cdk2 |
| JP7853532B2 (ja) | 2020-05-19 | 2026-04-30 | ファーマコスモス ホールディング エー/エス | 医学的障害を治療するためのサイクリン依存性キナーゼ阻害化合物 |
| US10988479B1 (en) | 2020-06-15 | 2021-04-27 | G1 Therapeutics, Inc. | Morphic forms of trilaciclib and methods of manufacture thereof |
| US20230303570A1 (en) * | 2020-08-07 | 2023-09-28 | Abm Therapeutics Corporation | Kinase inhibitors and uses thereof |
| JP2023551679A (ja) * | 2020-12-02 | 2023-12-12 | テリオス ファーマ, インコーポレイテッド | 眼科疾患を治療するための方法及び組成物 |
| WO2022240788A1 (en) * | 2021-05-11 | 2022-11-17 | Abbvie Inc. | Venetoclax dosing regimens for use in treating myelodysplastic syndromes in combination with a cyp3a inhibitor and azacitidine |
| US11981671B2 (en) | 2021-06-21 | 2024-05-14 | Incyte Corporation | Bicyclic pyrazolyl amines as CDK2 inhibitors |
| CN113788837B (zh) * | 2021-08-02 | 2022-08-26 | 深圳湾实验室坪山生物医药研发转化中心 | Trilaciclib的合成方法 |
| CN113786491B (zh) * | 2021-10-08 | 2023-03-28 | 中国医学科学院医药生物技术研究所 | 一种含汉防己甲素、二氢槲皮素或槲皮素的抗肿瘤联用制剂 |
| US11976073B2 (en) | 2021-12-10 | 2024-05-07 | Incyte Corporation | Bicyclic amines as CDK2 inhibitors |
| CA3253113A1 (en) * | 2022-06-20 | 2023-12-28 | Incyclix Bio, Llc | CYCLINE-DEPENDENT KINASE 2 INHIBITORS FOR MEDICAL TREATMENT |
| IT202300001971A1 (it) * | 2023-02-07 | 2024-08-07 | Olon Spa | Processo per la preparazione di trilaciclib o un suo sale. |
| WO2025238662A1 (en) * | 2024-05-15 | 2025-11-20 | Msn Laboratories Private Limited, R&D Center | Improved process for the preparation of 4-amino-n-[(1s)-1-(4-chlorophenyl)-3-hydroxypropyl]-1-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-4-piperidinecarboxamide and its salts |
Family Cites Families (108)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4418068A (en) | 1981-04-03 | 1983-11-29 | Eli Lilly And Company | Antiestrogenic and antiandrugenic benzothiophenes |
| TW366342B (en) | 1992-07-28 | 1999-08-11 | Lilly Co Eli | The use of 2-phenyl-3-aroylbenzothiophenes in inhibiting bone loss |
| US5565215A (en) | 1993-07-23 | 1996-10-15 | Massachusettes Institute Of Technology | Biodegradable injectable particles for imaging |
| US5478847A (en) | 1994-03-02 | 1995-12-26 | Eli Lilly And Company | Methods of use for inhibiting bone loss and lowering serum cholesterol |
| GB9412273D0 (en) | 1994-06-18 | 1994-08-10 | Univ Nottingham | Administration means |
| US6007845A (en) | 1994-07-22 | 1999-12-28 | Massachusetts Institute Of Technology | Nanoparticles and microparticles of non-linear hydrophilic-hydrophobic multiblock copolymers |
| US6413539B1 (en) | 1996-10-31 | 2002-07-02 | Poly-Med, Inc. | Hydrogel-forming, self-solvating absorbable polyester copolymers, and methods for use thereof |
| US5628984A (en) | 1995-07-31 | 1997-05-13 | University Of North Carolina At Chapel Hill | Method of detecting lung disease |
| US5780497A (en) | 1996-04-19 | 1998-07-14 | American Home Products Corporation | 2-phenyl-1- 4-(amino-1-yl-alk-1-ynyl)-benzyl!-1H-indol-5-ols as estrogenic agents |
| TW397821B (en) | 1996-04-19 | 2000-07-11 | American Home Produits Corp | 3-[4-(2-phenyl-indole-1-ylmethyl)-phenyl]-acrylamides and 2-phenyl-1-[4-(amino-1-yl-alk-1-ynyl)-benzyl]-1H-indol-5-ol as well as pharmaceutical compositions of estrogenic agents thereof |
| US5998402A (en) | 1996-04-19 | 1999-12-07 | American Home Products Corporation | 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indoles as estrogenic agents |
| US5880137A (en) | 1996-04-19 | 1999-03-09 | American Home Products Corporation | 2-phenyl-1- 4-(amino-1-yl-alk-1-ynyl)-benzyl!-1H-indol-5-ols as estrogenic agents |
| US6005102A (en) | 1997-10-15 | 1999-12-21 | American Home Products Corporation | Aryloxy-alkyl-dialkylamines |
| UA68365C2 (en) | 1997-11-06 | 2004-08-16 | Wyeth Corp | Peroral contraception by combination of anti-estrogen and progestin |
| US6326392B1 (en) | 1997-11-06 | 2001-12-04 | American Home Products Corporation | Anti-estrogen plus progestin containing oral contraceptives |
| US6583170B1 (en) | 1998-05-15 | 2003-06-24 | Wyeth | 2-Phenyl-1-[4-(amino-1-yl-alk-1-ynyl)-benzyl]-1H-indol-5-ol and estrogen formulations |
| US6479535B1 (en) | 1998-05-15 | 2002-11-12 | Wyeth | 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indole and estrogen formulations |
| US6287588B1 (en) | 1999-04-29 | 2001-09-11 | Macromed, Inc. | Agent delivering system comprised of microparticle and biodegradable gel with an improved releasing profile and methods of use thereof |
| CO5271697A1 (es) | 2000-01-12 | 2003-04-30 | Pfizer Prod Inc | Composiciones y procedimientos para el tratamiento de afecciones que responden a un aumento de testosterona |
| CO5271709A1 (es) | 2000-01-12 | 2003-04-30 | Pfizer Prod Inc | Composiciones y procedimientos para el y tratamiento de afecciones que responden a estrogenos |
| CO5271696A1 (es) | 2000-01-12 | 2003-04-30 | Pfizer Prod Inc | Procedimiento para reducir la morbilidad y el riesgo de mortalidad |
| CO5251465A1 (es) | 2000-01-26 | 2003-02-28 | Pfizer Prod Inc | Composiciones y procedimientos para tratar la osteoporosis y reducir el colesterol |
| EP1268477B1 (en) | 2000-03-15 | 2010-04-21 | Sanofi-Aventis Deutschland GmbH | Substituted beta-carbolines with ikb-kinase inhibiting activity |
| US20020013327A1 (en) | 2000-04-18 | 2002-01-31 | Lee Andrew G. | Compositions and methods for treating female sexual dysfunction |
| US6589549B2 (en) | 2000-04-27 | 2003-07-08 | Macromed, Incorporated | Bioactive agent delivering system comprised of microparticles within a biodegradable to improve release profiles |
| US6495164B1 (en) | 2000-05-25 | 2002-12-17 | Alkermes Controlled Therapeutics, Inc. I | Preparation of injectable suspensions having improved injectability |
| EP1296674A2 (en) | 2000-07-06 | 2003-04-02 | Wyeth | Use of substituted indole compounds for increasing nitric oxide synthase activity |
| US6509332B2 (en) | 2000-07-06 | 2003-01-21 | Wyeth | Methods of treating excessive intraocular pressure |
| JP2004502729A (ja) | 2000-07-06 | 2004-01-29 | ワイス | Ssriおよびエストロゲン剤の組み合わせ |
| WO2002003989A2 (en) | 2000-07-06 | 2002-01-17 | Wyeth | Use of substituted indole compounds for treating sphincter incontinence |
| AU2001271706A1 (en) | 2000-07-06 | 2002-01-21 | American Home Products Corporation | Use of substituted indole compounds for treating breast disorders |
| AR030064A1 (es) | 2000-07-06 | 2003-08-13 | Wyeth Corp | Metodos para inhibir los efectos uterotroficos de los agentes estrogenicos |
| AU2001273125A1 (en) | 2000-07-06 | 2002-01-21 | American Home Products Corporation | Combinations of bisphosphonates, estrogenic agents and optionally estrogens |
| EP1359940A2 (en) | 2000-07-06 | 2003-11-12 | Wyeth | Combinations of statins, estrogenic agents and optionally estrogens |
| WO2002003988A2 (en) | 2000-07-06 | 2002-01-17 | Wyeth | Use of substituted indole compounds for treating neuropeptide y-related conditions |
| AU2001271784A1 (en) | 2000-07-06 | 2002-01-21 | Wyeth | Therapy for prosthesis-related bone degeneration |
| EP1177787A3 (en) | 2000-07-28 | 2003-09-10 | Pfizer Products Inc. | Use of an estrogen agonist/antagonist for treating cataracts |
| ATE278421T1 (de) | 2000-08-11 | 2004-10-15 | Wyeth Corp | Verfahren zur behandlung eines östrogenrezeptor positives karzinoms |
| EP1192945A3 (en) | 2000-09-21 | 2004-03-03 | Pfizer Products Inc. | Use of an estrogen agonist/antagonist for treating osteoarthritis |
| IL145838A (en) | 2000-10-16 | 2008-11-03 | Pfizer Prod Inc | Use of an estrogen agonist/antagonist for the manufacture of a medicament for treating vaginitis |
| EP2316490A3 (en) | 2000-10-31 | 2012-02-01 | PR Pharmaceuticals, Inc. | Methods and compositions for enhanced delivery of bioactive molecules |
| AU781168B2 (en) | 2001-01-26 | 2005-05-12 | Pfizer Products Inc. | Method of treating certain cancers using an estrogen agonist/antagonist |
| GB0122318D0 (en) | 2001-09-14 | 2001-11-07 | Novartis Ag | Organic compounds |
| NZ534069A (en) | 2002-01-22 | 2007-03-30 | Warner Lambert Co | 2-(Pyridin-2-ylamino)-pyrido[2,3-d]pyrimidin-7-ones to be used to treat neurodegenerative disorders, viruses and cancer |
| EP1590341B1 (en) * | 2003-01-17 | 2009-06-17 | Warner-Lambert Company LLC | 2-aminopyridine substituted heterocycles as inhibitors of cellular proliferation |
| US20050009910A1 (en) | 2003-07-10 | 2005-01-13 | Allergan, Inc. | Delivery of an active drug to the posterior part of the eye via subconjunctival or periocular delivery of a prodrug |
| ES2246694B1 (es) | 2004-04-29 | 2007-05-01 | Instituto Cientifico Y Tecnologico De Navarra, S.A. | Nanoparticulas pegiladas. |
| BRPI0510485A (pt) | 2004-04-30 | 2007-11-13 | Allergan Inc | implantes inibidores de tirosina cinase intravìtreos biodegradáveis |
| US7771742B2 (en) | 2004-04-30 | 2010-08-10 | Allergan, Inc. | Sustained release intraocular implants containing tyrosine kinase inhibitors and related methods |
| US20050244469A1 (en) | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Extended therapeutic effect ocular implant treatments |
| JPWO2006008874A1 (ja) | 2004-05-21 | 2008-05-01 | 萬有製薬株式会社 | アミノチアゾ−ル骨格を有するCdk4、6選択的阻害剤 |
| US7399767B2 (en) | 2005-01-21 | 2008-07-15 | Ortho-Mcneil Pharmaceutical, Inc. | Heterocyclic benzo[c]chromene derivatives useful as modulators of the estrogen receptors |
| US20070071756A1 (en) | 2005-09-26 | 2007-03-29 | Peyman Gholam A | Delivery of an agent to ameliorate inflammation |
| US7946916B2 (en) | 2006-01-12 | 2011-05-24 | Waterleaf Ltd. | Variable payout wager games |
| WO2007084418A2 (en) | 2006-01-13 | 2007-07-26 | Surmodics, Inc. | Microparticle containing matrices for drug delivery |
| CA2640678C (en) | 2006-02-03 | 2015-03-31 | Bionomics Limited | Substituted benzofurans, benzothiophenes, benzoselenophenes and indoles and their use as tubulin polymerisation inhibitors |
| US20080166411A1 (en) | 2006-04-10 | 2008-07-10 | Pfizer Inc | Injectable Depot Formulations And Methods For Providing Sustained Release Of Poorly Soluble Drugs Comprising Nanoparticles |
| WO2009100176A2 (en) | 2008-02-07 | 2009-08-13 | Abbott Laboratories | Pharmaceutical dosage form for oral administration of tyrosine kinase inhibitor |
| CA2726114A1 (en) | 2008-06-11 | 2009-12-17 | Genentech, Inc. | Diazacarbazoles and methods of use |
| AU2009284098B2 (en) * | 2008-08-22 | 2012-03-29 | Astex Therapeutics Ltd. | Pyrrolopyrimidine compounds as CDK inhibitors |
| WO2010043633A1 (en) | 2008-10-15 | 2010-04-22 | Palau Pharma, S. A. | 2h-pyrazolo [4,3-d]pyrimidin-5-amine derivatives as h4 histamine receptor antagonists for the treatment of allergic, immunological and inflammatory diseases |
| WO2010091187A2 (en) | 2009-02-04 | 2010-08-12 | The Brigham And Women's Hospital, Inc. | Polymeric nanoparticles with enhanced drug-loading and methods of use thereof |
| US10952965B2 (en) | 2009-05-15 | 2021-03-23 | Baxter International Inc. | Compositions and methods for drug delivery |
| CN102713618B (zh) | 2009-09-16 | 2015-07-15 | 新基阿维罗米克斯研究公司 | 蛋白激酶复合物和抑制剂 |
| UY33227A (es) | 2010-02-19 | 2011-09-30 | Novartis Ag | Compuestos de pirrolopirimidina como inhibidores de la cdk4/6 |
| US20130071349A1 (en) | 2010-03-02 | 2013-03-21 | Allergan, Inc. | Biodegradable polymers for lowering intraocular pressure |
| EP3205648A1 (en) | 2010-06-10 | 2017-08-16 | Seragon Pharmaceuticals, Inc. | Estrogen receptor modulators and uses thereof |
| US8853423B2 (en) | 2010-06-17 | 2014-10-07 | Seragon Pharmaceuticals, Inc. | Indane estrogen receptor modulators and uses thereof |
| GB2483736B (en) | 2010-09-16 | 2012-08-29 | Aragon Pharmaceuticals Inc | Estrogen receptor modulators and uses thereof |
| US10005750B2 (en) | 2010-10-06 | 2018-06-26 | J-Pharma Co., Ltd. | Developing potent urate transporter inhibitors: compounds designed for their uricosuric action |
| KR102186969B1 (ko) * | 2010-10-25 | 2020-12-04 | 쥐원 쎄라퓨틱스, 인크. | Cdk 억제제 |
| US8691830B2 (en) | 2010-10-25 | 2014-04-08 | G1 Therapeutics, Inc. | CDK inhibitors |
| US8829102B2 (en) | 2010-10-27 | 2014-09-09 | Cabot Corporation | High loading carbon black masterbatch for pressure pipe applications |
| US9840515B2 (en) | 2010-12-09 | 2017-12-12 | University of Pittsburgh—of the Commonwealth System of Higher Education | Protein kinase D inhibitors |
| EA026134B1 (ru) | 2010-12-16 | 2017-03-31 | Ф. Хоффманн-Ля Рош Аг | Трициклические ингибиторы pi3k и способы их применения |
| CA2819299A1 (en) | 2010-12-24 | 2012-06-28 | Merck Sharp & Dohme B.V. | N-substituted azetidine derivatives |
| CN103889986B (zh) | 2011-09-30 | 2017-07-21 | C&C新药研究所 | 新杂环衍生物及其应用 |
| EP2791132A4 (en) | 2011-12-14 | 2015-08-05 | Seragon Pharmaceuticals Inc | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF |
| BR112014014767A2 (pt) | 2011-12-16 | 2017-06-13 | Olema Pharmaceuticals Inc | novos compostos de benzopirano, composições e usos dos mesmos |
| EP3216792B1 (en) | 2012-03-29 | 2020-05-27 | G1 Therapeutics, Inc. | Lactam kinase inhibitors |
| US20140107025A1 (en) | 2012-04-16 | 2014-04-17 | Jade Therapeutics, Llc | Ocular drug delivery system |
| CA2870019C (en) | 2012-04-26 | 2020-08-18 | Francis Xavier Tavares | Synthesis of lactams |
| CN104145514B (zh) | 2012-08-01 | 2018-03-13 | 华为技术有限公司 | 用于同步的方法、装置及系统 |
| BR112015005878A2 (pt) | 2012-09-17 | 2017-07-04 | Bind Therapeutics Inc | nanopartículas terapêuticas compreendendo agente terapêutico e métodos de preparar e usar as mesmas |
| AU2013317899A1 (en) | 2012-09-20 | 2015-05-07 | Akina, Inc. | Biodegradable microcapsules containing filling material |
| RU2702908C2 (ru) | 2012-11-01 | 2019-10-14 | Инфинити Фармасьютикалз, Инк. | Лечение злокачественных опухолей с использованием модуляторов изоформ pi3-киназы |
| KR101747587B1 (ko) * | 2013-03-15 | 2017-06-14 | 노벨리스 인크. | 감쇄된 광택 마감을 갖는 압연 표면 |
| WO2014144596A2 (en) | 2013-03-15 | 2014-09-18 | G1 Therapeutics, Inc. | Transient protection of hematopoietic stem and progenitor cells against ionizing radiation |
| CA2906157C (en) * | 2013-03-15 | 2022-05-17 | G1 Therapeutics, Inc. | Highly active anti-neoplastic and anti-proliferative agents |
| JP6430483B2 (ja) | 2013-03-15 | 2018-11-28 | ジー1、セラピューティクス、インコーポレイテッドG1 Therapeutics, Inc. | 化学療法の間の正常細胞の一時的な保護 |
| WO2014165308A2 (en) | 2013-04-01 | 2014-10-09 | Allergan, Inc. | Microsphere drug delivery system for sustained intraocular release |
| AP2015008858A0 (en) | 2013-05-28 | 2015-11-30 | Astrazeneca Ab | Chemical compounds |
| EA031077B1 (ru) | 2013-06-19 | 2018-11-30 | Серагон Фармасьютикалз, Инк. | Модулятор рецептора эстрогена и его применения |
| WO2014203132A1 (en) | 2013-06-19 | 2014-12-24 | Olema Pharmaceuticals, Inc. | Substituted benzopyran compounds, compositions and uses thereof |
| WO2014203129A1 (en) | 2013-06-19 | 2014-12-24 | Olema Pharmaceuticals, Inc. | Combinations of benzopyran compounds, compositions and uses thereof |
| BR112015030595A2 (pt) | 2013-06-19 | 2017-07-25 | Seragon Pharmaceuticals Inc | moduladores de receptor de estrogênio de azetidina e usos dos mesmos |
| WO2015061407A1 (en) | 2013-10-24 | 2015-04-30 | Francis Xavier Tavares | Process for synthesis of lactams |
| US9481591B1 (en) | 2013-12-16 | 2016-11-01 | Barbara Blake | Device and process to treat and disinfect sewage, food processing wastewater and other biologically contaminated water |
| SG11201607334YA (en) | 2014-03-13 | 2016-10-28 | Hoffmann La Roche | Therapeutic combinations with estrogen receptor modulators |
| WO2015161283A1 (en) | 2014-04-17 | 2015-10-22 | G1 Therapeutics, Inc. | Tricyclic lactams for use in hspc-sparing treatments for rb-positive abnormal cellular proliferation |
| RU2671494C2 (ru) | 2014-05-28 | 2018-11-01 | Шанхай Фокон Фармасьютикал Ко., Лтд | Некоторые ингибиторы протеинкиназы |
| EP3191098A4 (en) | 2014-09-12 | 2018-04-25 | G1 Therapeutics, Inc. | Combinations and dosing regimes to treat rb-positive tumors |
| WO2016040848A1 (en) | 2014-09-12 | 2016-03-17 | G1 Therapeutics, Inc. | Treatment of rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors |
| TWI784255B (zh) | 2014-12-18 | 2022-11-21 | 瑞士商赫孚孟拉羅股份公司 | 四氫-吡啶并[3,4-b]吲哚雌激素受體調節劑及其用途 |
| CN109789143A (zh) * | 2016-07-01 | 2019-05-21 | G1治疗公司 | 基于嘧啶的抗增殖剂 |
| WO2018005863A1 (en) * | 2016-07-01 | 2018-01-04 | G1 Therapeutics, Inc. | Pyrimidine-based compounds for the treatment of cancer |
| US11865176B2 (en) | 2016-11-08 | 2024-01-09 | Dana-Farber Cancer Institute, Inc. | Compositions and methods of modulating anti-tumor immunity |
| CA3045037A1 (en) | 2016-12-08 | 2018-06-14 | Icahn School Of Medicine At Mount Sinai | Compositions and methods for treating cdk4/6-mediated cancer |
-
2017
- 2017-06-29 CN CN201780041481.2A patent/CN109789143A/zh active Pending
- 2017-06-29 WO PCT/US2017/040093 patent/WO2018005860A1/en not_active Ceased
- 2017-06-29 CA CA3028751A patent/CA3028751A1/en not_active Abandoned
- 2017-06-29 EP EP17821288.2A patent/EP3478294A4/en not_active Withdrawn
- 2017-06-29 EP EP20213600.8A patent/EP3858835A1/en not_active Withdrawn
- 2017-06-29 JP JP2018569079A patent/JP2019520379A/ja active Pending
- 2017-06-29 EA EA201990187A patent/EA201990187A1/ru unknown
- 2017-06-29 KR KR1020197002845A patent/KR20190025943A/ko not_active Withdrawn
- 2017-06-29 RU RU2019102647A patent/RU2019102647A/ru not_active Application Discontinuation
- 2017-06-29 MX MX2019000200A patent/MX2019000200A/es unknown
- 2017-06-29 BR BR112018077136-8A patent/BR112018077136A2/pt not_active Application Discontinuation
- 2017-06-29 AU AU2017290748A patent/AU2017290748A1/en not_active Abandoned
-
2018
- 2018-12-21 US US16/230,396 patent/US10829490B2/en active Active
- 2018-12-23 IL IL263910A patent/IL263910A/en unknown
-
2020
- 2020-11-03 US US17/088,298 patent/US20210047328A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20210047328A1 (en) | 2021-02-18 |
| AU2017290748A1 (en) | 2019-01-17 |
| MX2019000200A (es) | 2019-09-26 |
| CN109789143A (zh) | 2019-05-21 |
| EP3478294A4 (en) | 2020-06-10 |
| IL263910A (en) | 2019-01-31 |
| EA201990187A1 (ru) | 2019-07-31 |
| WO2018005860A1 (en) | 2018-01-04 |
| KR20190025943A (ko) | 2019-03-12 |
| JP2019520379A (ja) | 2019-07-18 |
| US10829490B2 (en) | 2020-11-10 |
| BR112018077136A2 (pt) | 2019-04-30 |
| EP3858835A1 (en) | 2021-08-04 |
| CA3028751A1 (en) | 2018-01-04 |
| RU2019102647A3 (cg-RX-API-DMAC7.html) | 2020-08-03 |
| US20190135811A1 (en) | 2019-05-09 |
| EP3478294A1 (en) | 2019-05-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019520379A5 (cg-RX-API-DMAC7.html) | ||
| RU2018122089A (ru) | Соединения и композиции, подходящие для лечения расстройств, связанных с ntrk | |
| RU2013123790A (ru) | Ингибиторы cdk | |
| RU2016127553A (ru) | Бифункциональные цитотоксические агенты | |
| RU2018111459A (ru) | Гетероциклические соединения и их применение | |
| RU2018103907A (ru) | Хиральные диарильные макроциклы в качестве модуляторов протеинкиназ | |
| RU2017145026A (ru) | Соединение, ингибирующее brk | |
| RU2016118753A (ru) | Производные пиридилкетона, способ их получения и их фармацевтическое применение | |
| JP2020512974A5 (cg-RX-API-DMAC7.html) | ||
| MX386480B (es) | Inhibidores de hpk1 y métodos de uso de los mismos. | |
| RU2011105768A (ru) | Производные пиперидина в качестве ингибиторов jakз | |
| RU2014111823A (ru) | Гетероциклические соединения и их применения | |
| TR201909849T4 (tr) | Btk etkinliği inhibitörleri olarak heteroaril piridon ve aza-piridon bileşikleri. | |
| AR081075A1 (es) | Derivados de imidazo[1,2-c]pirimidina, composiciones farmaceuticas que los contienen, metodo para prepararlos y uso de los mismos en el tratamiento de enfermedades autoinmunes e inflamatorias. | |
| JP2016513737A5 (cg-RX-API-DMAC7.html) | ||
| RU2018101897A (ru) | Бициклическое гетероциклическое амидное производное | |
| RU2017111200A (ru) | Циклогексилэтилзамещенные диаза- и триаза-трициклические соединения в качестве антагонистов индоламин-2,3-диоксигеназы для лечения рака | |
| RU2014115847A (ru) | Пирролопиримидиновые соединения для лечения злокачественной опухоли | |
| RU2018122864A (ru) | Ингибиторы протеинкиназ, их способ получения и медицинское применение | |
| RU2015106434A (ru) | Производные типа азаиндазола или диазаиндазола для лечения боли | |
| JP2014525438A5 (cg-RX-API-DMAC7.html) | ||
| RU2007104028A (ru) | Ингибиторы iap | |
| FI3888658T3 (fi) | eIF4A:ta inhiboivia yhdisteitä ja niihin liittyviä menetelmiä | |
| AR042052A1 (es) | Diaminotriazoles utiles como inhibidores de proteinquinasas | |
| JP2018524403A5 (cg-RX-API-DMAC7.html) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20210913 |